Streetbeat News

Price Targets

BIOR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $65 price target.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 4:40 pm

NVCR

HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on NovoCure (NASDAQ:NVCR) and maintained an $85 price target.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 4:39 pm

LRCX

Morgan Stanley analyst Joseph Moore has maintained an Overweight rating on Lam Research (NASDAQ:LRCX) and raised the price target from $550 to $720.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 4:38 pm

KRYS

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Krystal Biotech (NASDAQ:KRYS) and maintained a price target of $139.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 4:37 pm

IVZ

Morgan Stanley analyst Michael Cyprys has reiterated an Equal-Weight rating on Invesco (NYSE:IVZ) and maintained a $17 price target.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 4:37 pm

VKTX

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $33.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 4:36 pm

HLT

Morgan Stanley analyst Stephen Grambling maintains an Overweight rating on Hilton Worldwide Holdings (NYSE:HLT) and raises the price target from $163 to $170.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 4:35 pm

RBBN

JMP Securities analyst Erik Suppiger has reiterated a Market Outperform rating on Ribbon Comms (NASDAQ:RBBN) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 4:34 pm

NOW

JMP Securities analyst Patrick Walravens has reiterated a Market Outperform rating on ServiceNow (NYSE:NOW) and maintained a price target of $665.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 4:33 pm

GL

Morgan Stanley analyst Nigel Dally maintains an Underweight rating on Globe Life (NYSE:GL) and raises the price target from $130 to $131.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 4:31 pm